1. Home
  2. GLUE vs IDT Comparison

GLUE vs IDT Comparison

Compare GLUE & IDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Monte Rosa Therapeutics Inc.

GLUE

Monte Rosa Therapeutics Inc.

HOLD

Current Price

$19.06

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Logo IDT Corporation Class B

IDT

IDT Corporation Class B

HOLD

Current Price

$49.72

Market Cap

1.2B

ML Signal

HOLD

Company Overview

Basic Information
Metric
GLUE
IDT
Founded
2019
1990
Country
US
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Telecommunications Equipment
Sector
Health Care
Telecommunications
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.2B
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
GLUE
IDT
Price
$19.06
$49.72
Analyst Decision
Strong Buy
Analyst Count
4
0
Target Price
$29.50
N/A
AVG Volume (30 Days)
972.4K
106.7K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
0.49%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$75,622,000.00
N/A
Revenue This Year
$84.02
$1.99
Revenue Next Year
N/A
N/A
P/E Ratio
$72.42
$15.10
Revenue Growth
N/A
N/A
52 Week Low
$3.50
$45.07
52 Week High
$25.77
$71.12

Technical Indicators

Market Signals
Indicator
GLUE
IDT
Relative Strength Index (RSI) 45.89 53.28
Support Level $17.79 $47.89
Resistance Level $19.24 $49.87
Average True Range (ATR) 1.25 1.45
MACD -0.32 0.19
Stochastic Oscillator 35.41 88.69

Price Performance

Historical Comparison
GLUE
IDT

About GLUE Monte Rosa Therapeutics Inc.

Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.

About IDT IDT Corporation Class B

IDT Corp is a multinational holding company. It operates in the telecommunications and payment industries. It has four reportable business segments, Fintech, National Retail Solutions; net2phone and Traditional Communications, The Fintech segment is comprised of National Retail Solutions (NRS), an operator of a nationwide point of sale (POS) network providing payment processing, digital advertising, transaction data, and ancillary services, and BOSS Money, a provider of international money remittance and related value/payment transfer services. The net2phone segment provides unified cloud communications and telephony services to business customers.

Share on Social Networks: